MktsMarkets

Ocular Therapeutix, Inc.
NASDAQ: OCULKey statistics
OCUL News
Stories mentioning OCUL from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 10,785 | 13,250 | 14,544 | 13,459 | 10,698 | 17,083 | 15,425 | 16,441 |
| Cost of Goods Sold | 1,329 | 1,594 | 1,774 | 1,944 | 1,262 | 1,230 | 1,561 | 1,509 |
| Gross Profit | 9,456 | 11,656 | 12,770 | 11,515 | 9,436 | 15,853 | 13,864 | 14,932 |
| Operating Expenses | ||||||||
| Research & Development | 66,213 | 50,800 | 52,358 | 51,081 | 42,857 | 40,989 | 37,054 | 28,857 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (93,340) | (69,761) | (68,698) | (67,641) | (63,917) | (50,576) | (45,998) | (43,590) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (88,612) | (64,654) | (69,418) | (67,814) | (64,053) | (48,388) | (36,493) | (43,777) |
| Earnings Per Share (Basic) | (0.40) | (0.35) | (0.38) | (0.39) | (0.38) | (0.31) | (0.22) | (0.26) |
| Earnings Per Share (Diluted) | (0.40) | (0.35) | (0.38) | (0.39) | (0.38) | (0.31) | (0.22) | (0.26) |
| Weighted Average Shares Outstanding (Basic) | 224,099 | 187,241 | 183,920 | 172,595 | 169,397 | 158,265 | 166,993 | 165,825 |
| Weighted Average Shares Outstanding (Diluted) | 224,099 | 187,241 | 183,920 | 172,595 | 169,397 | 158,265 | 166,993 | 165,825 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About OCUL
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a stock listed on the Nasdaq Stock Market under the ticker symbol OCUL. It last traded at $6.59 (Nov 6, 2026, 4:00 PM ET), up 2.6% on the day. That gives Ocular Therapeutix a market capitalisation of $1.4B.
Over the past 52 weeks OCUL has traded between $6.00 and $16.44.
Revenue for the quarter ended Mar 31, 2026 was $10.8M; a net loss of $88.6M. Revenue was up 0.8% from $10.7M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $10.8M | -$88.6M | -821.6% |
| Dec 31, 2025 | $13.3M | -$64.7M | -488.0% |
| Sep 30, 2025 | $14.5M | -$69.4M | -477.3% |
| Jun 30, 2025 | $13.5M | -$67.8M | -503.9% |
From Ocular Therapeutix’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…